{
  "docId": "019de070-3b27-7318-9c92-a5817b78bd41",
  "docSlug": "ce86c4a3bf509aea21f24e2159890cb6",
  "documentTitle": "BioNTech | Results Presentation Deck | 28 slides",
  "authorId": "biontech",
  "authorName": "BioNTech",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2020-08-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 21,
  "pageCount": 28,
  "prevPage": 20,
  "nextPage": 22,
  "slideType": "other",
  "function": "present_framework",
  "density": "overcrowded",
  "nDataPoints": 2,
  "notes": "The slide outlines the clinical trial protocol for the Pfizer-BioNTech COVID-19 vaccine.",
  "elementsJson": null,
  "metadataConfidence": 0.95,
  "imagePath": null,
  "slideHref": "/slides/019de070-3b27-7318-9c92-a5817b78bd41/21",
  "deckHref": "/decks/019de070-3b27-7318-9c92-a5817b78bd41",
  "deckJsonHref": "/decks/019de070-3b27-7318-9c92-a5817b78bd41.json",
  "deckAnchorHref": "/decks/019de070-3b27-7318-9c92-a5817b78bd41#slide-21",
  "components": [
    {
      "bbox": {
        "h": 0.09,
        "w": 0.8,
        "x": 0.1,
        "y": 0.81
      },
      "kind": "callout",
      "text": "Goal of filing for emergency authorization or approval as early as October, if trial is deemed to be successful",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7f148d47-94de-45df-ba21-e37087ed8cee",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.85,
        "x": 0.04,
        "y": 0.23
      },
      "kind": "list",
      "text": "Planned to enroll up to 30,000 participants between 18 and 85 years of age at approximately 120 clinical investigational sites around world",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7ffcee6c-b4c0-4649-9c2c-5ebc81e2b4ac",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.85,
        "x": 0.04,
        "y": 0.43
      },
      "kind": "list",
      "text": "Co-Primary endpoints: Prevention of COVID-19 in those who have not been infected by SARS-CoV-2 prior to immunization; Prevention of COVID-19 regardless of whether participants have previously been infected by SARS-CoV-2",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "989adc2b-ee43-4570-b855-f324b97882ba",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.88,
        "x": 0.04,
        "y": 0.33
      },
      "kind": "list",
      "text": "Designed as 1:1 vaccine candidate to placebo, randomized, observer-blinded study to obtain safety, immune response, and efficacy data needed for regulatory review",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a6fa4b52-240e-4314-892e-d000c3d5ca64",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.55,
        "x": 0.04,
        "y": 0.63
      },
      "kind": "list",
      "text": "Secondary endpoints include prevention of severe COVID-19",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d5147574-15b7-4893-a241-98a8b935672b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.85,
        "x": 0.04,
        "y": 0.69
      },
      "kind": "list",
      "text": "Design allows for interim analyses and unblinded reviews by independent external Data Monitoring Committee",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ec4a5fbf-4475-4906-bddf-5f727440bdbc",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.48,
        "x": 0.04,
        "y": 0.09
      },
      "kind": "title",
      "text": "BNT162b2: Global Phase 2b/3 design",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f9d4301e-3293-4eea-8ad2-43381ffd0f85",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Audience Definition",
      "slug": "audience-definition",
      "agent": "Storyteller",
      "layer": "slide",
      "matchId": "abdf30ad-4923-4901-b497-6e5197b72c11",
      "evidence": "Co-Primary endpoints: Prevention of COVID-19",
      "confidence": 0.5
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 28,
      "from": 21,
      "beatId": "e917a87d-2b75-411a-b926-1b30683902ca",
      "arcName": "Monroe's Motivated Sequence",
      "arcSlug": "monroes-sequence",
      "beatName": "Action",
      "beatSlug": "monroes-sequence-action",
      "evidence": "The presentation concludes with an outlook for 2H 2020 and a Q&A session",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}